CU Anschutz Reaches Best NIH Ranking in Two Decades With $314 Million

Research funding rankings rarely capture the full complexity of an institution's scientific contributions, but they do track something real: the scale and consistency of NIH confidence in a medical school's research programs. By that measure, the University of Colorado Anschutz School of Medicine has reached a position not seen in two decades.

The Blue Ridge Institute for Medical Research (BRIMR) rankings, which compile annual NIH award data for U.S. medical schools and their departments, placed CU Anschutz at 21st overall in its latest assessment - up from 22nd in the previous year's rankings - and 8th among public medical schools nationwide. The school's total NIH funding reached nearly $314 million, a year-over-year increase of $9.7 million. The last time the school ranked this high overall was 2006, when it placed 20th.

Department-Level Performance

The school's ranking advance is driven by department-level strength across a genuinely wide range of specialties - not a single flagship department lifting institutional averages. The Department of Pediatrics leads nationally among peer departments, receiving more than $63 million from the NIH. That figure reflects the depth of child health and disease research conducted at Children's Hospital Colorado and affiliated facilities on the Anschutz Medical Campus in Aurora.

Pharmacology ranked fourth nationally with more than $22.5 million. Orthopedics placed fifth with $6.7 million. Physical Medicine and Rehabilitation ranked sixth with more than $3.5 million. Otolaryngology, Emergency Medicine, and Anesthesiology each ranked 11th. Family Medicine and Dermatology both placed 12th, and Internal Medicine ranked 14th.

Nine of the school's 18 clinical departments now rank in the top 15 nationally - up from six just one year ago. That increase of three departments in a single year reflects substantial growth across the portfolio rather than incremental movement in a few already-strong programs. Half the school's clinical departments now occupy nationally recognized positions, a benchmark of distributed research strength.

What NIH Rankings Measure - and What They Don't

BRIMR rankings are constructed from total NIH grant dollars, which means they capture competitive peer-reviewed federal funding but say nothing directly about research quality, clinical impact, patient outcomes, or the translation of findings into medical practice. A department can rank highly by securing many mid-sized investigator grants or fewer large program project awards; the ranking does not distinguish between these patterns, nor does it weight grants by citation impact or therapeutic significance.

That said, NIH peer review is selective. Grants typically go through a two-stage review process: an initial scientific review by external experts who score the proposal's scientific merit, followed by council review that considers program priorities. Sustained high funding levels indicate that a substantial and consistent portion of a school's research proposals are passing that external scrutiny at competitive paylines. For department chairs and deans competing for faculty recruits, BRIMR rankings serve as a widely recognized benchmark of research infrastructure, institutional support, and collaborative opportunity that prospective faculty weigh alongside salary and facilities.

Trajectory and Target

John H. Sampson, MD, PhD, MBA, vice chancellor for health affairs and dean of the School of Medicine, described the result as the best in 20 years and framed it as a marker on a longer trajectory toward a top-10 overall ranking. He noted that several departments are positioned such that a single major new grant could move them into the top 10 in their respective categories - a description that typically refers to large program project grants, CTSA awards, or center grants that move departmental funding totals significantly in a single fiscal year when secured.

Whether that trajectory continues depends on factors partially outside the school's control. NIH appropriations have faced political uncertainty, and individual department rankings can shift substantially based on congressional budget allocations, the funding success rate (payline) in a given year, and the availability of new grant mechanisms in areas where the school has existing strength. The move from 22nd to 21st in a single year reflects not only CU Anschutz's own applications succeeding but also other institutions' portfolios remaining level or declining in relative terms.

The Anschutz Campus in Context

The Anschutz Medical Campus in Aurora houses the School of Medicine alongside the University of Colorado's schools of pharmacy, public health, dental medicine, and nursing, as well as affiliated hospitals including UCHealth University of Colorado Hospital and Children's Hospital Colorado. The geographic concentration of multiple health sciences schools and clinical facilities on a single campus creates collaborative opportunities that individual departmental rankings do not fully capture: shared equipment, cross-department grant applications, and training programs that draw from multiple disciplines.

The campus's growth trajectory has been consistent over the past two decades. CU Anschutz moved from 22nd to 21st overall in a single year while adding three departments to the top-15 roster - a pace of improvement that reflects sustained strategic investment in research faculty recruitment, core facility development, and clinical trial infrastructure. The Pediatrics department's first-place ranking in particular is a product of sustained investment in child health research at a campus that sits adjacent to one of the country's leading children's hospitals.

Funding Growth Across the Field

The $9.7 million increase in NIH funding over the previous year is meaningful but not unusual for an institution growing its research portfolio. What distinguishes the current moment for CU Anschutz is the breadth of the growth: rather than being driven by one or two large new awards, the improvement reflects multiple departments simultaneously advancing their positions. That pattern suggests the growth is structural - embedded in faculty, infrastructure, and research programs - rather than dependent on any single grant that could expire and pull the numbers back.

The school's goal of breaking into the top 10 overall represents a substantial but not unrealistic ambition. The institutions currently occupying positions 10 through 15 in overall NIH funding to medical schools include a mix of public and private institutions with long-established research programs. Closing that gap requires sustained year-over-year growth and successful competition for large multi-investigator awards - the kind that take years to develop but can move institutional rankings meaningfully when secured.

For the Anschutz School of Medicine, the 2025 rankings confirm a 20-year high point and a research portfolio that is broader and deeper than at any point in the institution's history. Whether that position translates into a top-10 ranking in the next several years will depend on sustaining momentum in an environment where federal research funding priorities can shift. What the current rankings establish clearly is that the school has the departmental depth and the collaborative infrastructure to compete at that level - a foundation that was not as visible in NIH funding data just a few years ago. The three-department jump into the top 15 in a single year, alongside an increase in absolute funding of nearly $10 million, indicates an institution gaining momentum rather than one that has reached a plateau. For researchers choosing where to build their careers, and for trainees selecting graduate and fellowship programs, that trajectory is often as important as the current rank itself.